Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + etoposide + vincristine + prednisone
- Development stage
- Discontinued
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CEOP is a chemotherapy regimen consisting of cyclophosphamide, etoposide, vincristine, and prednisone. It is primarily used in the treatment of peripheral T-cell lymphomas (PTCL) and other aggressive lymphomas. This regimen is a modification of the standard CHOP regimen, where etoposide replaces doxorubicin. The typical dosing schedule includes cyclophosphamide 750 mg/m² IV on day 1, etoposide 100 mg/m² IV on days 1-3, vincristine 2 mg IV on day 1, and prednisone 100 mg/day for 5 days.
02
Targets
DNAGR (Glucocorticoid receptor)MicrotubuleTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + etoposide + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + etoposide + vincristine + prednisone.